What disease does Lurbinectedin treat?

Lurbinectedin is a drug used to treat certain types of cancer. Its main indications include recurrent small cell lung cancer (SCLC) and recurrent synovial sarcoma (Myxoid/round cell liposarcoma).

1.Recurrent small cell lung cancer (SCLC):SCLC is a more malignant subtype of lung cancer that is often associated with tobacco use. Although it may be somewhat responsive to initial chemotherapy, SCLC has a high recurrence rate and often becomes resistant to further treatment. Rubicatin, as a new therapeutic drug, has been approved for the treatment of patients with relapsed SCLC, providing a new treatment option for these patients.

2.Recurrent synovial sarcoma: Synovial sarcoma is a rare soft tissue tumor that usually occurs in the retroperitoneum, extremities, or other locations. Rubicatin is also approved to treat patients with recurrent synovial sarcoma. The drug's mechanism of action is expected to play a role in controlling the growth and spread of synovial sarcoma.

Rubicatine belongs to a class of drugs known as"DNAtopoisomeraseIIαinhibitors". It affects the repair and replication process of DNA by inhibiting the activity of DNAtopoisomerase IIα, ultimately leading to the death of tumor cells. Due to its unique mechanism of action, rubicatin offers new hope for the treatment of patients with relapsed SCLC and synovial sarcoma.

Rubicardin has not yet been launched in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase Rubicatin through overseas channels. There is only the original drug Rubicatin in foreign countries, and the price is relatively expensive. In comparison, the original drug in Singapore is slightly cheaper, priced at more than 30,000, and there are other American versions of the original drug, priced at more than 90,000.